The rollout timeline is as follows:
-Imported & manufactured finished products: registration begins February 2026
-Locally produced or packed products: registration begins August 2026
This marks a turning point for Egypt’s pharmaceutical sector ,and it’s worth reviewing how the market is structured today.
Manufacturing
Egypt has one of the strongest localized markets in the region, with 91% of pharmaceutical products manufactured locally. The country’s industrial backbone includes:
179 Factories
2,370 Production lines
1600+ Distribution warehouses
80000 Pharmaceis
Supply chain Dynamics
The pharmaceutical supply chain flows from MAHs and manufacturers to the downstream layers:
Wholesalers
(≈80%): Large, organized players such as Ibnsina Pharma, Pharmaoverseas.official, and Egyptian Pharmaceutical Distribution Agency (EPDA), operating nationwide with advanced technology and digital systems. Pharmacies typically engage with them based on payment terms, service quality, and product availability. Payment models vary (cash, post-dated cheques, or monthly settlement), depending on the pharmacy’s credit profile.
Distributors (≈20%): Often sole distributors working on cash-based models with high inventory turnover. This segment is less structured and more dependent on manual processes with limited digitalization.
Retail
Pharmacy chains (Ezaby, Misr Pharmacies, Seif) represent less than 1% of Egypt’s 80,000 pharmacies. This contrasts with markets like KSA and UAE, where retail chains dominate. Egypt’s retail sector remains highly fragmented, giving wholesalers a stronger influence.
Market Snapshot
12,000+ registered drug products
3.5 billion units sold annually , soon to become serialized packs under Track & Trace
Around 82,000 GLNs across the ecosystem
USD 6.2 billion market size , officially Africa’s largest pharmaceutical market